Blockbuster diabetes and weight loss drugs from Eli Lilly and Novo Nordisk - including Mounjaro, Zepbound, Ozempic and Wegovy - generated over U$40 billion in combined sales last year.
However, Novo Nordisk has warned that the rise in copycat versions of its weight-loss drug in the U.S. and competition from Lilly across several markets is expected to hurt Wegovy sales this year.